Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nineteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $43.88.

A number of research analysts have weighed in on the stock. Citigroup lowered shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their price target for the company from $35.00 to $24.00 in a research note on Tuesday, March 4th. Morgan Stanley lowered shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Robert W. Baird reduced their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd.

Remove Ads

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.20% of the company's stock.

Institutional Trading of Tandem Diabetes Care

Several institutional investors have recently added to or reduced their stakes in TNDM. AlphaQuest LLC lifted its stake in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares during the period. NBC Securities Inc. purchased a new position in shares of Tandem Diabetes Care during the first quarter valued at approximately $37,000. Jones Financial Companies Lllp lifted its stake in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares in the last quarter. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the last quarter. Finally, McIlrath & Eck LLC purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter worth approximately $52,000.

Tandem Diabetes Care Trading Down 0.1 %

NASDAQ TNDM traded down $0.02 during trading on Friday, reaching $17.01. 567,592 shares of the stock traded hands, compared to its average volume of 1,498,921. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -8.81 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock's 50-day moving average price is $23.23 and its 200 day moving average price is $30.64. Tandem Diabetes Care has a fifty-two week low of $15.75 and a fifty-two week high of $53.69.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.